NO2904345T3 - - Google Patents

Info

Publication number
NO2904345T3
NO2904345T3 NO13771071A NO13771071A NO2904345T3 NO 2904345 T3 NO2904345 T3 NO 2904345T3 NO 13771071 A NO13771071 A NO 13771071A NO 13771071 A NO13771071 A NO 13771071A NO 2904345 T3 NO2904345 T3 NO 2904345T3
Authority
NO
Norway
Application number
NO13771071A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2904345(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2904345T3 publication Critical patent/NO2904345T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
NO13771071A 2011-12-19 2013-09-27 NO2904345T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19

Publications (1)

Publication Number Publication Date
NO2904345T3 true NO2904345T3 (no) 2018-07-21

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13771071A NO2904345T3 (no) 2011-12-19 2013-09-27

Country Status (28)

Country Link
US (1) US9475888B2 (no)
EP (1) EP2794665B1 (no)
JP (2) JP6543467B2 (no)
KR (1) KR102135485B1 (no)
CN (1) CN104144950B (no)
AU (1) AU2012354229B2 (no)
BR (1) BR112014014454B1 (no)
CA (1) CA2856492C (no)
CL (1) CL2014001651A1 (no)
CO (1) CO7061069A2 (no)
CY (1) CY1119899T1 (no)
DK (1) DK2794665T3 (no)
ES (1) ES2656613T3 (no)
HK (1) HK1202883A1 (no)
HR (1) HRP20180124T1 (no)
HU (1) HUE036523T2 (no)
IL (1) IL232905A (no)
LT (1) LT2794665T (no)
ME (1) ME02994B (no)
MX (1) MX351104B (no)
NO (1) NO2904345T3 (no)
PL (1) PL2794665T3 (no)
PT (1) PT2794665T (no)
RS (1) RS56874B1 (no)
RU (1) RU2617764C2 (no)
SI (1) SI2794665T1 (no)
WO (1) WO2013095279A1 (no)
ZA (1) ZA201403640B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104244957B (zh) * 2012-03-26 2017-11-17 迪乐方有限责任公司 用于治疗分娩停止的方法
UA117908C2 (uk) * 2012-03-26 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для індукції пологів
AU2013260209A1 (en) * 2012-05-08 2014-11-20 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
BR112016025443A2 (pt) * 2014-04-30 2017-12-12 Agency Science Tech & Res sulfatos de heparano
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
BR112022014456A2 (pt) 2020-02-17 2022-09-13 Dilafor Ab Tafoxiparina para o tratamento da pré-eclâmpsia
US20230355658A1 (en) 2022-05-03 2023-11-09 Dilafor Ab Medical use of tafoxiparin
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (en) * 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
DE69623840D1 (de) * 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Zusammensetzung zur Hemmung der Thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
CA2240328A1 (en) 1996-10-15 1998-04-23 Toray Industries, Inc. Cervical canal maturing agent
GB9711443D0 (en) * 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
WO1999026984A1 (fr) * 1997-11-20 1999-06-03 Ikuo Yamashina Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
DE69931038T2 (de) 1998-02-26 2006-11-23 Seikagaku Corp. Neue polysaccharidderivate, verfahren zu ihrer herstellung und medizinische zusammensetzungen die diese als aktives bestandteil enthalten
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
KR20010030803A (ko) * 1998-07-31 2001-04-16 야마야 와따루 신규 글리코사미노글리칸 및 이를 함유하는 의약 조성물
CA2341668A1 (en) * 1998-08-26 2000-03-09 The Collaborative Group, Ltd. Receptor for underivatized, aqueous soluble beta-(1,3)-glucan
PL353335A1 (en) * 1999-06-30 2003-11-17 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
EP1319183B1 (en) * 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
US20080214480A1 (en) 2005-07-22 2008-09-04 Trf Pharma, Inc. Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae
JP2009507209A (ja) * 2005-07-22 2009-02-19 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ヘパリン組成物およびセレクチン阻害
JP5308328B2 (ja) * 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
CN101495517B (zh) * 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
CN101842392B (zh) * 2007-11-02 2014-08-27 动量制药公司 非抗凝血剂的多糖组合物
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8445436B2 (en) 2007-12-03 2013-05-21 Florida State University Research Foundation, Inc. Oxytocin and melatonin compositions and associated methods for inducing labor
AU2009231634B2 (en) 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8680200B2 (en) * 2009-03-27 2014-03-25 Actamax Surgical Materials Llc Polyglycerol aldehydes
ES2458818T3 (es) 2009-04-16 2014-05-07 Momenta Pharmaceuticals, Inc. Métodos para evaluar la actividad de una composición de polisacárido
US20120108538A1 (en) 2009-06-30 2012-05-03 James Beeson Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
EA201290069A1 (ru) * 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
DK2515957T3 (en) * 2009-12-22 2015-11-09 Lifebond Ltd CHANGE OF ENZYMATIC CIRCULATORS FOR MANAGEMENT OF CHARACTERISTICS BY CIRCUIT MATRIX
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104244957B (zh) 2012-03-26 2017-11-17 迪乐方有限责任公司 用于治疗分娩停止的方法
UA117908C2 (uk) 2012-03-26 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для індукції пологів

Also Published As

Publication number Publication date
AU2012354229B2 (en) 2016-12-01
RU2014129816A (ru) 2016-02-20
BR112014014454A2 (pt) 2017-06-13
IL232905A (en) 2017-02-28
CN104144950A (zh) 2014-11-12
US20150011505A1 (en) 2015-01-08
BR112014014454B1 (pt) 2021-03-09
CA2856492C (en) 2017-01-10
CO7061069A2 (es) 2014-09-19
JP2018111825A (ja) 2018-07-19
WO2013095279A1 (en) 2013-06-27
HUE036523T2 (hu) 2018-07-30
ME02994B (me) 2018-10-20
RU2617764C2 (ru) 2017-04-26
PT2794665T (pt) 2018-01-24
CY1119899T1 (el) 2018-06-27
ES2656613T3 (es) 2018-02-27
SI2794665T1 (en) 2018-03-30
JP6543467B2 (ja) 2019-07-10
EP2794665B1 (en) 2017-11-22
HRP20180124T1 (hr) 2018-02-23
HK1202883A1 (en) 2015-10-09
ZA201403640B (en) 2017-06-28
EP2794665A4 (en) 2015-08-26
CA2856492A1 (en) 2013-06-27
LT2794665T (lt) 2017-12-27
PL2794665T3 (pl) 2018-04-30
AU2012354229A1 (en) 2014-06-05
JP2015500388A (ja) 2015-01-05
CN104144950B (zh) 2017-09-05
EP2794665A1 (en) 2014-10-29
MX2014007122A (es) 2015-03-05
DK2794665T3 (da) 2018-01-29
MX351104B (es) 2017-10-02
CL2014001651A1 (es) 2014-10-10
US9475888B2 (en) 2016-10-25
RS56874B1 (sr) 2018-04-30
KR102135485B1 (ko) 2020-07-17
IL232905A0 (en) 2014-07-31
KR20140113652A (ko) 2014-09-24

Similar Documents

Publication Publication Date Title
BR112013022641A2 (no)
AP3853A (no)
BR112013031251A2 (no)
BR112013027245A2 (no)
BR112013023185A2 (no)
BR112013022995A2 (no)
BR112013017670A2 (no)
BR112013027830A2 (no)
BR112013024365A2 (no)
BR112013028733A2 (no)
AP2016009466A0 (no)
BR112013031556A2 (no)
BR112013024588A2 (no)
BR112013032377A2 (no)
BR112013032380A2 (no)
BR112013032368A2 (no)
BR112013018949A2 (no)
BR112013021637A2 (no)
BR112014003657A2 (no)
BR112013027836A2 (no)
BR112013032392A2 (no)
BR112013017878A2 (no)
BR112013027871A2 (no)
BR112013033389A2 (no)
BR112013032394A2 (no)